ALVOTECH

NASDAQ: ALVO (Alvotech)

Last update: 23 Aug, 10:32AM

8.45

-0.02 (-0.24%)

Previous Close 8.47
Open 8.49
Volume 469,269
Avg. Volume (3M) 336,630
Market Cap 2,633,028,352
Price / Earnings (TTM) 36.74
Price / Earnings (Forward) 15.24
Price / Sales 4.18
52 Weeks Range
7.35 (-13%) — 13.70 (62%)
Earnings Date 12 Nov 2025
Profit Margin 16.42%
Operating Margin (TTM) 7.97%
Diluted EPS (TTM) 0.370
Quarterly Revenue Growth (YOY) 260.00%
Quarterly Earnings Growth (YOY) -65.50%
Current Ratio (MRQ) 1.73
Operating Cash Flow (TTM) -148.89 M
Levered Free Cash Flow (TTM) -216.76 M
Return on Assets (TTM) 7.02%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Bullish Mixed
Drug Manufacturers - Specialty & Generic (Global) Bullish Mixed
Stock Alvotech Bearish Bearish

AIStockmoo Score

1.3
Analyst Consensus 1.5
Insider Activity NA
Price Volatility 1.5
Technical Moving Averages 0.0
Technical Oscillators 2.0
Average 1.25

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
ALVO 3 B - 36.74 -
LNTH 5 B - 20.97 3.01
KNSA 3 B - 729.80 5.78
BCRX 2 B - - 56.59
HROW 1 B - - 35.10
ETON 378 M - - 22.16

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Small Growth
% Held by Insiders 63.44%
% Held by Institutions 6.44%

Ownership

Name Date Shares Held
Lodbrok Capital Llp 30 Jun 2025 181,587
52 Weeks Range
7.35 (-13%) — 13.70 (62%)
Price Target Range
0.000 (-100%) — 14.00 (65%)
High 14.00 (Deutsche Bank, 65.68%) Buy
14.00 (UBS, 65.68%) Buy
Median 14.00 (65.68%)
Average 14.00 (65.68%)
Total 2 Buy
Avg. Price @ Call 8.67
Firm Date Target Price Call Price @ Call
Deutsche Bank 23 Sep 2025 14.00 (65.68%) Buy 8.70
UBS 18 Jul 2025 14.00 (65.68%) Buy 8.63

No data within this time range.

Date Type Details
06 Oct 2025 Announcement Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)
06 Oct 2025 Announcement European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
06 Oct 2025 Announcement European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
22 Sep 2025 Announcement European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
22 Sep 2025 Announcement European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
22 Sep 2025 Announcement European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
22 Sep 2025 Announcement European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
19 Sep 2025 Announcement Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
19 Sep 2025 Announcement Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
04 Sep 2025 Announcement Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
04 Sep 2025 Announcement Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
21 Aug 2025 Announcement Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
21 Aug 2025 Announcement Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
20 Aug 2025 Announcement Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
13 Aug 2025 Announcement Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
13 Aug 2025 Announcement Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
06 Aug 2025 Announcement Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
06 Aug 2025 Announcement Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
10 Jul 2025 Announcement Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
10 Jul 2025 Announcement Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
09 Jul 2025 Announcement Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland
09 Jul 2025 Announcement Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria